General Information of Drug (ID: DMJ9ML8)

Drug Name
PSB-6426 Drug Info
Synonyms
PSB-6426; CHEMBL469212; GTPL9033; SCHEMBL13210969; BDBM50262249; compound 19a [PMID: 18630897]; (2S,3S,4R,5R)-N-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide; 4-[2-((2S,3R,4S,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofurane-2-carboxamido)ethylamido-]benzylphosphonic Acid Diethyl Ester
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
24949079
TTD Drug ID
DMJ9ML8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH5201 DMFEI6T Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
SRF617 DMTK1BV Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
TTX-030 DM8H2AG Lymphoma 2A80-2A86 Phase 1 [4]
PSB-0963 DMBDVJ1 Discovery agent N.A. Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) TTYM8DJ ENTP1_HUMAN Inhibitor [1]

References

1 Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28.
2 ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Surface oncology.
4 Clinical pipeline report, company report or official report of AbbVie.
5 Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.